Upgrade to SI Premium - Free Trial

Healtheuniverse, Inc. (LUN)

0.00 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy October 1, 2026 2:18 AM - PR NewsWire Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome September 15, 2026 3:26 AM - PR NewsWire European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin August 24, 2026 5:33 AM - PR NewsWire Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 August 19, 2026 2:00 AM - PR NewsWire Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S August 19, 2026 1:33 AM - PR NewsWire One Mine Stake Is Already Worth Nearly 3X This Company's Entire Market Cap August 17, 2026 9:00 AM - Globe NewsWire FDA grants Lundbeck Fast Track status for narcolepsy drug candidate July 23, 2026 3:30 AM - StreetInsider Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy July 23, 2026 3:30 AM - PR NewsWire Full Article List